SRTS vs. NYXH, SMTI, AVR, RCEL, LUNG, ELMD, INGN, ZYXI, LAKE, and DRTS
Should you be buying Sensus Healthcare stock or one of its competitors? The main competitors of Sensus Healthcare include Nyxoah (NYXH), Sanara MedTech (SMTI), Anteris Technologies Global (AVR), AVITA Medical (RCEL), Pulmonx (LUNG), Electromed (ELMD), Inogen (INGN), Zynex (ZYXI), Lakeland Industries (LAKE), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.
Sensus Healthcare vs.
Sensus Healthcare (NASDAQ:SRTS) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
Sensus Healthcare currently has a consensus price target of $14.67, suggesting a potential upside of 172.61%. Nyxoah has a consensus price target of $17.00, suggesting a potential upside of 64.25%. Given Sensus Healthcare's stronger consensus rating and higher possible upside, research analysts plainly believe Sensus Healthcare is more favorable than Nyxoah.
Sensus Healthcare has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.
In the previous week, Nyxoah had 2 more articles in the media than Sensus Healthcare. MarketBeat recorded 3 mentions for Nyxoah and 1 mentions for Sensus Healthcare. Nyxoah's average media sentiment score of 0.15 beat Sensus Healthcare's score of -0.34 indicating that Nyxoah is being referred to more favorably in the news media.
Sensus Healthcare has a net margin of 15.90% compared to Nyxoah's net margin of -1,043.93%. Sensus Healthcare's return on equity of 12.60% beat Nyxoah's return on equity.
25.3% of Sensus Healthcare shares are owned by institutional investors. 9.4% of Sensus Healthcare shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Sensus Healthcare received 146 more outperform votes than Nyxoah when rated by MarketBeat users. However, 71.70% of users gave Nyxoah an outperform vote while only 68.66% of users gave Sensus Healthcare an outperform vote.
Sensus Healthcare has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
Summary
Sensus Healthcare beats Nyxoah on 12 of the 19 factors compared between the two stocks.
Get Sensus Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensus Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:SRTS) was last updated on 2/21/2025 by MarketBeat.com Staff
